Reuters Science News Summary | Health
Here is a summary of current scientific news.
Easier-to-produce COVID vaccine shows promise in trials; Nasal spray vaccine booster works in mice
Here is a summary of some recent studies on COVID-19. They include research that deserves further study to corroborate the findings and that has not yet been certified by peer review. New COVID-19 vaccine could be made like flu shots
Scientists want Britain to back COVID patent waivers
Scientists on Friday called on British Prime Minister Boris Johnson to back the waiver of intellectual property rights for COVID-19 vaccines, tests and treatments following the rapid spread of the Omicron coronavirus variant. In a letter, also addressed to the UK’s health, trade, business and foreign ministers, the scientists asked Johnson to support the agreement on trade-related aspects of intellectual property rights (TRIPS) of the United Kingdom. World Trade Organization (WTO).
Scientists amazed by ‘totally unexpected’ behavior of blinking star
Scientists have detected what appears to be an incredibly dense star unlike anything else they’ve ever seen – and suspect it could be a type of exotic astrophysical object whose existence hasn’t existed until now. at present been only hypothetical. The object, spotted using the Murchison Widefield Array telescope in outback Western Australia, fired huge bursts of energy about three times an hour when viewed from Earth during two months in 2018, the researchers said.
Boosters increase Omicron death protection in over-50s to 95% – UKHSA
COVID-19 boosters increase the death protection of the Omicron variant to 95% in people aged 50 or over, the UK Health Security Agency said on Thursday. The UKHSA said that around six months after a second dose of one of the COVID-19 vaccines, protection against death with Omicron was around 60% in people aged 50 and over. However, this figure rose to around 95% two weeks after receiving a booster dose of the vaccine.
China’s Walvax says it has most participants for large mRNA COVID vaccine trial
China’s Walvax Biotechnology has recruited most of the 28,000 participants needed for a large clinical trial of its mRNA vaccine candidate against COVID-19, a senior company official said Thursday. China has not yet approved a Chinese new messenger RNA (mRNA) technology vaccine and has not yet imported a foreign mRNA vaccine.
(This story has not been edited by the Devdiscourse team and is auto-generated from a syndicated feed.)